Evidence map›Paper›PMID 40319417›Full record

ArticleDigestive diseases and sciences2025

Tracking Anti-cytolethal Distending Toxin B and Anti-vinculin Over Time and Their Roles in Symptoms.

Eden Sharabi, Jonathan A Busam, Kushagra Mathur, Ali Rezaie, Ruchi Mathur, Ava Hosseini, Mohamad Rashid, Mark Pimentel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eden SharabiDepartment of Medicine, Cedars-Sinai, Los Angeles, CA, USA.
Jonathan A BusamDepartment of Medicine, Cedars-Sinai, Los Angeles, CA, USA.
Kushagra MathurDepartment of Medicine, Cedars-Sinai, Los Angeles, CA, USA.
Ali RezaieMedically Associated Science and Technology (MAST) Program, West Hollywood, CA, USA.
Ruchi MathurMedically Associated Science and Technology (MAST) Program, West Hollywood, CA, USA.
Ava HosseiniMedically Associated Science and Technology (MAST) Program, West Hollywood, CA, USA.
Mohamad RashidMedically Associated Science and Technology (MAST) Program, West Hollywood, CA, USA.
Mark PimentelMedically Associated Science and Technology (MAST) Program, West Hollywood, CA, USA. pimentelm@cshs.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsAntibodies targeting bacterial cytolethal distending toxin subunit B (CdtB) and vinculin are diagnostic of post-infection irritable bowel syndrome (IBS). In this study, we explored the temporal behavior of anti-CdtB and anti-vinculin antibodies and potential relationships to IBS symptoms. The potential impacts of antibody reduction therapies were also assessed.

methodsA retrospective chart review of 417 IBS patients who had been tested for anti-CdtB and anti-vinculin antibodies was performed. Anti-vinculin and anti-CdtB antibody levels, time to normalization of antibody levels, and IBS symptoms' burdens and changes were assessed. Use of antibody-depleting therapies (intravenous immunoglobulin [IVIG] or plasmapheresis exchange [PLEX]) vs. usual management was also recorded.

results158 subjects (38.5%) were positive for either anti-CdtB or anti-vinculin. In subjects with multiple tests (total N = 38), normalization of anti-vinculin levels over time correlated with improvements in IBS symptoms (p = 0.020). Plasmapheresis (PLEX) or intravenous immunoglobulins (IVIG) treatments were associated with greater antibody normalization than usual management (p = 0.046).

conclusionsAnti-CdtB and anti-vinculin antibodies are common in post-infection IBS, and anti-vinculin levels may correlate with severity of IBS symptoms.

Indexed as

Antibodies, BacterialBacterial ToxinsIrritable Bowel SyndromeAdultFemaleHumansImmunoglobulins, IntravenousMaleMiddle AgedPlasmapheresisRetrospective StudiesTime FactorsAntibodies, BacterialBacterial Toxinscytolethal distending toxinImmunoglobulins, IntravenousAntibodiesCytolethal distending toxin BIrritable bowel syndromeSymptom severityVinculin

Identifiers

PMID40319417
PMCPMC12185622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.